



23<sup>RD</sup> ANNUAL

# PERSPECTIVES IN UROLOGY

## POINT COUNTERPOINT

The Scottsdale Plaza Resort • Scottsdale, AZ

November 14-16, 2014



### Program Director

#### **E. David Crawford, MD**

Professor of Surgery, Urology and  
Radiation Oncology  
E. David Crawford Endowed Chair  
in Urologic Oncology  
University of Colorado, Denver  
Aurora, CO

### Faculty

#### **David C. Beyer, MD**

Arizona Oncology Services  
Scottsdale, AZ

#### **Erik P. Castle, MD**

Mayo Clinic  
Phoenix, AZ

#### **Gerald W. Chodak, MD**

Michiana Shores, IN

#### **Robert E. Donohue, MD**

University of Colorado, Denver  
Aurora, CO

#### **Steven E. Finkelstein, MD**

21st Century Oncology  
Scottsdale, AZ

#### **Thai H. Ho, MD**

Mayo Clinic  
Phoenix, AZ

#### **Phillip J. Koo, MD**

University of Colorado, Denver  
Aurora, CO

#### **Karl J. Kreder, MD**

University of Iowa Hospital and Clinics  
Iowa City, IA

#### **Donald L. Lamm, MD**

BCG Oncology, PC  
Phoenix, AZ

#### **Daniel P. Petrylak, MD**

Yale Cancer Center  
New Haven, CT

#### **Matt T. Rosenberg, MD**

Mid-Michigan Health Centers  
Jackson, MI

#### **Mitchell H. Sokoloff, MD**

UMass-Memorial Health Care  
Worcester, MA

Co-Provided by Medical College of Wisconsin  
and Carden Jennings Publishing Co., Ltd.



Organized by CJP Medical Communications in  
partnership with *Grand Rounds in Urology*



**GRAND ROUNDS**  
inUROLOGY™

[www.pcp.grandroundseducation.com](http://www.pcp.grandroundseducation.com)

## Program Overview

The 23rd Annual **Perspectives in Urology: Point Counterpoint** will bring together leading experts to discuss and debate the latest in diagnosis, treatment, and ongoing research in the field of urology. The conference will contain lectures, debates, case presentations, discussions, and interactive question and answer sessions. The use of cutting-edge audience response technology will allow for more fluent interaction among attendees, between attendees and speakers, and for more efficient exchange of knowledge within the symposium space.

## Target Audience

This activity is designed for and will benefit urologists, urologic oncologists, medical oncologists, radiation oncologists, and other health care professionals involved in the diagnosis and management of urologic diseases.

## Statement of Need

This three-day course has been designed to address key questions on potentially practice changing developments in the field of urology, and to provide urologists, trainees, and other health care professionals involved in the diagnosis and management of urologic diseases with the framework to integrate these developments into their daily practice. All educational offerings will enhance patient assessment and outcomes and will include didactic lectures, debates, case presentations, and question and answer sessions.

## Learning Objectives

This educational initiative aims to reach urologists, urologic oncologists, and nurses. Upon completion of this activity, participants will be able to:

- Evaluate the growing use of biomarkers in genitourinary cancer detection
- Implement optimal practices for diagnosis and management of prostate, bladder, and renal cancers
- Integrate available hormonal, cytotoxic and immunotherapeutic agents for advanced and castration-resistant prostate cancer
- Define recent developments in genitourinary disease treatments that can impact patient quality-of-life outcomes
- Assess the options for personalizing treatment and sequencing new therapies in individual patients

## Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Medical College of Wisconsin and CJP Medical Communications. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.

## Credit Designation

MCW designates this live activity for a maximum of 18.5 *AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

## Disclosure of Conflicts of Interest

It is the policy of Medical College of Wisconsin to insure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MCW identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MCW to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis.

## CJP Medical Communications Disclosure

The employees of CJP Medical Communications have no financial relationships to disclose.

## Off-label/Investigational Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Medical College of Wisconsin, Carden Jennings Publishing, or the program supporters.

Before prescribing any medication, physicians should consult primary references and full prescribing information. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, participants should appraise the information presented critically, and are encouraged to consult appropriate resources for any product or device mentioned in this program.



This program is fully compliant with ADA regulations. Please contact us at 434-817-2000 to make special arrangements for this program.



### CJP Medical Communications

A Division of Carden Jennings Publishing Co., Ltd.  
375 Greenbrier Drive, Suite 100  
Charlottesville, VA 22901  
434-817-2000 • [www.cjp.com](http://www.cjp.com)

# FACULTY BIOGRAPHIES



## **E. David Crawford, MD**

Professor of Surgery  
Urology and Radiation Oncology  
E. David Crawford Endowed Chair in  
Urologic Oncology  
University of Colorado  
Denver School of Medicine  
Aurora, CO

E. David Crawford is Professor of Surgery, Urology, and Radiation Oncology, and Head of the Section of Urologic Oncology at the University of Colorado Denver (UCD) in Denver, Colorado. He is also the E. David Crawford Endowed Chair in Urologic Oncology at UCD.

Dr. Crawford received his medical degree from the University of Cincinnati. His postgraduate training included an internship and residency in Urology at the Good Samaritan Hospital in Cincinnati. He was subsequently awarded a Genitourinary Cancer fellowship with Dr. Donald G. Skinner at the University of California Medical Center in Los Angeles.

Dr. Crawford is a nationally recognized expert in prostate cancer. The recipient of more than 69 research grants, he has conducted research in the treatment of advanced bladder cancer, metastatic adenocarcinoma of the prostate, hormone-refractory prostate cancer, and other areas of urological infections and malignancies. He has authored or coauthored more than 400 articles, which have been published in such journals as Urology, The New England Journal of Medicine, and the Journal of the National Cancer Institute. He has published five textbooks. He is also an editorial reviewer or consultant for a large number of publications, including Urology, Journal of Urology, The New England Journal of Medicine, Cancer, and the Journal of Clinical Oncology. He serves as Medical Editor of Grand Rounds in Urology.

Dr. Crawford is an active member of many national and international organizations, including the American Society of Clinical aAUA, he is a member of the Committee to Study Urologic Research Funding and the Prostate Cancer Clinical Trials Subcommittee. He currently serves on the board of governors, the GU committee, and the scientific advisory board of the Southwest Oncology Groups, and he chairs the national Prostate Conditions Education Council (PCEC).

E. David Crawford, MD, discloses that he is on the Advisory Board for Dendreon, Ferring, and Janssen.



## **David C. Beyer, MD**

Vice President  
Arizona Oncology Services  
Scottsdale, AZ

David C. Beyer, MD, FASTRO, FACRO, FACR, is Vice President of Arizona Oncology Services, Inc. He serves on the Board of Directors for the American Society of Therapeutic Radiology & Oncology (ASTRO), is on the Board of Chancellors with the American College of Radiation Oncology (ACRO), and is an Editorial Board Member of the Journal of Brachytherapy. He is past president of the American Brachytherapy Society.

Dr. Beyer earned his medical degree from the University of Arizona, College of Medicine after completing a degree in electrical engineering from Massachusetts Institute of Technology. He joined Arizona Oncology Services in 1985, after serving consecutive residencies in both internal medicine and radiation oncology at the University of Arizona Health Sciences Center and University of California, Los Angeles. He is a member of Alpha Omega Alpha Honorary Society. Dr. Beyer is a Fellow of the American College of Radiation Oncology (ACRO), the American College of Radiology (ACR), and the American Society for Therapeutic Radiology and Oncology (ASTRO).

David C. Beyer, MD, discloses that he is a Speaker for Bayer.



## **Erik P. Castle, MD**

Associate Professor of Urology  
Mayo Clinic  
Phoenix, AZ

Dr. Erik Castle received his MD from University of Texas, Southwestern Medical Center at Dallas in 1998. Dr. Castle is a Professor of Urology at the Mayo Clinic in Arizona and has been practicing for 16 years. He practices medicine in Scottsdale AZ and two other locations and specializes in Surgical Urology. Dr. Castle is also the director of the Desert Mountain Care Prostate Cancer Research Fund.

Dr. Castle has been the Director of the International Laparoscopic Nephrectomy courses throughout Mexico on behalf of the American Urological Association (AUA) since 2008 and has been a voting member of the Laparoscopic, Robotic and New Surgical Technology Committee since 2010. Also with the AUA, Dr. Castle was a member of the Microscopic Hematuria Guidelines Committee from 2010-2012 and was the President of the Society of Urologic Robotic Surgeons from 2009-2010. Now he is the Associate Editor with the Journal of Robotic Surgery and has been since 2010.

Dr. Castle's research interests include prostate cancer, bladder cancer, and kidney cancer. In basic science research, he focuses on novel secondary hormonal therapies for prostate cancer and apoptotic pathways related to manipulations of the androgen and estrogen receptors. He also performs research into the genomics of prostate and bladder cancer. Dr. Castle directs the outcomes research of robotic and laparoscopic surgery for these three cancers and he is the principal investigator in the ongoing urologic oncology biorepository in his laboratory.

Erik P. Castle, MD, has no relevant financial relationships to disclose.





**Gerald W. Chodak, MD**  
Michiana Shores, IN

Dr. Gerald Chodak received his M.D. degree from the State University of New York at Buffalo in 1975 and completed his training in Urology at the University of Chicago in 1982. From 1982-1999 he was a full time faculty member in the Department of Surgery/Urology at the University of Chicago, reaching the rank of Professor in 1989. In 1999 he formed the Midwest Prostate and Urology Health Center in Chicago, and remained its director until 2008 when he closed his clinical practice. Dr. Chodak is credited with performing the first laparoscopic lymph node operation for prostate cancer in Japan, Sweden, Finland and Norway, the first urinary diversion for bladder cancer in Illinois in which patients do not need to wear a bag, and the first operation that removed both kidneys using a laparoscope. He has published over 150 original peer-reviewed medical articles, mostly on prostate cancer and has been invited to speak throughout the United States and in more than 14 countries.

Dr. Chodak has been very committed to education. He helped form the first chapter of Us TOO, the international support group for men and their significant others with prostate cancer. He created the first video education website ([www.ProstateVideos.com](http://www.ProstateVideos.com)) that contains over 100 free videos for the public on every aspect of prostate health and prostate disease including cancer. Currently, he is the Director of Medical Media for Answers TV and has appeared on "Say Ahhh" on the LiveWell Network. He does a weekly video blog for MEDSCAPE entitled, "Controversies in Urology."

Gerald W. Chodak, MD, discloses that he is a Speaker for Actavis.



**Robert E. Donohue, MD**  
Professor Emeritus  
University of Colorado, Denver  
Denver, CO

Dr. Donohue graduated from the New York University School of Medicine and completed his Surgery and Urology residency at NYU. Dr. Donohue then was appointed Special Fellow in Urology at the Memorial Sloan-Kettering Cancer Center. Spending some time abroad, Dr. Donohue then became the Senior Surgical Registrar in Urology at the Christchurch Public Hospital in Christchurch, New Zealand. Back in the USA, he was appointed Assistant Professor of Surgery for Urology at The University of Colorado in 1972 and Director of Medical Student Programs in Urology there, as well as the Chief of Urology Service at the Denver CAMC, in 1977. He was promoted to Associate Professor in 1979 and Full Professor in 1989. As a professor, Dr. Donohue directed Urology rotations at the medical school and was appointed director of the Career Choices electives in Urology in 2004. He was also the editor of Classic Articles in Urology for Urology from 1984-1989. Other positions Dr. Donohue held include being Chairmen of the Rocky Mountain Urological Society from 1975-1988 and President from 1994-1996.

This Brooklyn born and raised doctor retired in 2009 but he is still attending the Urology weekly Grand Rounds,

The Second Opinion Conference of Dr. Crawford for new Urologic malignancies. In 2008, Dr. Donohue was appointed the Historian of the South Central Section (SCS) and he continues this role presently, regionally and nationally. Dr. Donohue has devoted a lot of time to the AUA and the SCS of the AUA. He was first appointed the representative to the Journal of Urology from 1989-1994 by the AUA. Then in 1998 he was elected Secretary of the SCS where he served for four years. In 2004, Dr. Donohue was named President of the SCS and his presidential meeting was held jointly with the Irish Urological Society in Dublin, Ireland. Also in 2004, Dr. Donohue was appointed the SCS representative to the AUA Judicial and Ethics Committee and served that position until 2010. Dr. Donohue also still assists in the Medical Spanish course for first year Medical Students.

Robert E. Donohue, MD, has no relevant financial relationships to disclose.



**Steven E. Finkelstein, MD**  
21st Century Oncology  
Scottsdale, AZ

Steve E. Finkelstein is a Board Certified Radiation Oncologist, and is National Director of TRC, the cutting-edge therapy arm of 21st Century Oncology in Scottsdale, Arizona. He is also Adjunct Associate Professor at Translational Genomic Research Institute (Tgen), and Executive Director of the Arizona Cancer Research Alliance (ACRA). Dr. Finkelstein is responsible for expanding patient access to advanced cancer care. Inspired by his grandmother who became ill with cancer when he was 13 years old, he became a dedicated cancer surgeon who found that radiation therapy could sometimes do for his patients what surgery could not.

Dr. Finkelstein received an undergraduate Bachelor of Science degree from the University of Michigan Inteflex Integrated Program in Ann Arbor, Michigan, and his medical degree from the University of Michigan Medical School. He served a residency in General Surgery at Washington University in Saint Louis, Missouri, and was Chief Resident in Radiation Oncology at the Moffitt Cancer Center in Tampa, Florida. Dr. Finkelstein also served Fellowships in Biologic Immunotherapy Clinical Cancer and Surgical Oncology at the Surgery Branch of the NCI/NIH in Bethesda, Maryland. He is a member of the American College of Radiation Oncology, American Medical Association, American Society of Clinical Oncology, American Society for Therapeutic Radiology and Oncology, the Radiological Society of North America, and the Radiation Therapy Oncology Group.

Steven E. Finkelstein, MD, discloses he has been a Speaker for Bayer/Algeta, Dendreon, Ferring, and Medivation. He discloses he also has received research funding from Bayer/Algeta and Dendreon, and he is on the Speaker's Bureau for Bayer/Algeta, Dendreon and Medivation in the discussion of prostate cancer.

**Thai H. Ho, MD**

Assistant Professor of Urology  
Mayo Clinic  
Phoenix, AZ

Dr. Ho is an assistant professor and academic medical oncologist specializing in genitourinary cancers at the Mayo Clinic. Dr. Ho graduated from the Baylor College of Medicine with his PhD in 2005 and with his MD in 2006 and has been in practice for 8 years. He is a member of the Center for Individualized Medicine Genomic Tumor Board as well as the Mayo Clinic Center for Individualized Medicine Epigenomics Group. On the Genomic Tumor Board, Dr. Ho interprets the results of tumor sequencing and is responsible for recommending individualized therapies. In the Epigenomics Group, Dr. Ho's research involves the analysis of genome-wide chromatin modification maps of genotyped tumor tissue. Dr. Ho is also a co-investigator on the Mayo Clinic Genitourinary Biobank where he participates in biospecimen submission for The Cancer Genome Atlas Project (TCGA), specifically in papillary kidney, bladder and prostate cancer.

Dr. Ho is additionally involved in the papillary renal cell carcinoma working group. In terms of patient advocacy groups, he is involved in the von-Hippel Lindau Alliance and the Kidney Cancer Association. In future research ventures, Dr. Ho hopes to identify epigenetic phenotypes based on chromatin-modifying enzyme mutations in kidney cancer that can translate to other malignancies with similar mutations.

Thai H. Ho, MD, has no relevant financial relationships to disclose.

**Phillip J. Koo, MD**

Chief, Nuclear Medicine and  
Molecular Imaging  
Program Director, Nuclear  
Radiology Fellowship  
Assistant Professor of Radiology  
University of Colorado, Denver  
Aurora, CO

Phillip J. Koo, MD joined the faculty at the University of Colorado School of Medicine in 2011. He is currently Chief of Nuclear Medicine, Program Director of the fellowship in nuclear radiology, and Assistant Professor of Radiology. Dr. Koo is also Director of PET/CT Imaging at the Colorado Translational Research Imaging Center (CTRIC).

Dr. Koo completed his transitional internship at the University of Pennsylvania Medical Center-Presbyterian, radiology residency at Pennsylvania Hospital of the University of Pennsylvania Health System, and fellowship at the Harvard Medical School Joint Program in Nuclear Medicine (JPNM). He is a diplomate of both the American Board of Radiology (2010) and American Board of Nuclear Medicine (2011). His current research interests in prostate cancer involve the use of metabolic inhibitors to enhance the imaging of local and advanced disease using FDG PET/CT.

Phillip J. Koo, MD, discloses that he is a Speaker for Bayer and Dendreon. He also has financial relationships with Bayer and Dendreon.

**Karl J. Kreder, MD**

Professor and Head, Rubin H. Flocks  
Chair, Urology  
University of Iowa Hospital and Clinics  
Iowa City, IA

Dr. Karl Kreder is Professor and Department Executive Officer of the Department of Urology at the University of Iowa. His clinical interests include female and male urinary incontinence, interstitial cystitis, and reconstructive urology. He serves as Discovery Site Director for the NIDDK's Multi-Disciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Study.

Dr. Kreder is a member of the International Continence Society (2009 Scientific Committee Chair), and is active in the Société Internationale d'Urologie, the Society for Urodynamics and Female Urology, and the Genitourinary Reconstructive Surgeons Society. Dr. Kreder has published over 125 peer-reviewed manuscripts and 25 book chapters, and has edited two textbooks.

Karl J. Kreder, MD, MBA, discloses that he is a Speaker for Medtronic, Symptelligence, and Tengion. He also discloses he has financial relationships with Medtronic, Symptelligence, and Tengion.

**Donald L. Lamm, MD, FACS**

President  
Bladder Cancer-Genitourinary  
Oncology  
Phoenix, AZ

Donald L. Lamm is president of BCG Oncology in Phoenix, Arizona. He is former professor of urology at the Mayo Clinic, Scottsdale, and professor and chief of urology at West Virginia University, and the University of Texas, San Antonio. Dr. Lamm completed his residencies at University of California at Los Angeles Wadsworth Veterans Administration Medical Center in general surgery, and the University of California at San Diego in urology. Dr. Lamm has had a lifelong interest in urologic oncology and clinical trials and has a particular interest in immunotherapy and chemoprevention. He was awarded the initial NIH-funded contract to evaluate BCG immunotherapy of superficial bladder cancer in a randomized clinical trial (1978). This work, accruing an eventual 231 patients, resulted in the first controlled trial demonstrating the efficacy of intravesical BCG immunotherapy.

Subsequent NIH-funded research demonstrated the superiority of intravesical BCG over oral administration and the efficacy of intravesical without percutaneous BCG immunotherapy. Additional SWOG studies under his direction demonstrated the superiority of BCG immunotherapy over doxorubicin and mitomycin chemotherapy. The former SWOG study resulted in the FDA approval of BCG for the treatment of CIS and the latter resulted in the approval of TICE BCG for the prophylaxis of recurrent papillary transitional cell carcinoma. More recently, the SWOG study directed by Dr. Lamm demonstrated that three-week maintenance BCG immunotherapy reduces tumor long-term recurrence by 27% and significantly reduces disease worsening compared with standard induction therapy. Dr. Lamm has authored more than 270 peer-reviewed medical and scientific articles, and in addition to new treatments of bladder cancer he has developed new

approaches to the treatment of renal and prostate cancer as well. His primary interest, however, continues to be BCG therapy of bladder cancer.

Donald L. Lamm, MD, has no relevant financial relationships to disclose.



**Daniel P. Petrylak, MD**

Director of Genitourinary Oncology  
Co-Director, Signal  
Transduction Program  
Yale Cancer Center  
New Haven, CT

Dr. Petrylak is the Director of the Genitourinary Oncology Section and Co-Director of the Signal Transduction Program at the Yale Cancer Center in New Haven. He is a member of the American Association for Cancer Research, American Society for Clinical Oncology, American College of Physicians, American Association for the Advancement of Science, American Urological Association, and the Southwest Oncology Group. Dr. Petrylak currently serves as the Principal Investigator or co-Principal Investigator on several Southwest Oncology Group (SWOG) clinical trials for genitourinary cancers. He also heads the advanced bladder cancer subcommittee for SWOG.

Dr. Petrylak received his undergraduate degree from Columbia College and his medical degree from Case Western University School of Medicine. He completed his internship and residency at Albert Einstein College of Medicine and his fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center. He has authored more than 100 peer-reviewed articles and book chapters on prostate and bladder cancer research outcomes.

Daniel P. Petrylak, MD, discloses he has been a Speaker for Bayer, Bellicum, Dendreon, Exelixis, Ferring, Johnson & Johnson, Medivation, Millennium, Pfizer, and Sanofi. He also has received grant support from Celgene, Dendreon, Johnson & Johnson, Oncogenex, Progenics, and Sanofi.



**Matt T. Rosenberg, MD**

Medical Director  
Mid-Michigan Health Centers  
Chief, Department of Family Medicine  
Foote Health System  
Jackson, MI

Dr. Rosenberg earned his medical degree at the University of California, Irvine. He trained in general surgery at the University of California, Irvine, and in urologic surgery at the Brigham and Women's Hospital in Boston before changing fields to general practice. Dr. Rosenberg now practices in Jackson, Michigan, and serves as Medical Director of Mid-Michigan Health Centers. He is also actively on the staff of the Foote Health System, where he served as Chief of the Department of Family Medicine from 2002 to 2006.

Dr. Rosenberg has a special interest in the medical management of urologic diseases and has authored and co-authored articles appearing in *Urology*, the *Journal of Urology*, *BJU International*, and other peer-reviewed journals. He has presented his original research at many national meetings, including those of the National Institutes of Health, the American Urological Association, the Sexual Medicine Society of North America, and the European Society for

Sexual Medicine. He is a reviewer for several national and international journals and was recently selected to be the section editor of *Urology* for the *International Journal of Clinical Practice*.

Dr. Rosenberg was honored as the most recent recipient of the Continence Care Champion award by the National Association for Continence (NAFC). This nationwide award is bestowed by the NAFC Board of Directors to a health care provider who has distinguished himself in research, clinical practice, and education with accomplishments meaningful to continence care.

Matt T. Rosenberg, MD, discloses he is on the Speaker's bureau of Astellas, Forest, Horizon, Ortho-McNeil, and Pfizer. He also is a Consultant for Astellas, Eisai, Ferring, Horizon, Lilly, Pfizer and Bayer.



**Mitchell Sokoloff, MD, FACS**

Professor and Chair  
Department of Urology  
University of Massachusetts  
Medical School  
UMass-Memorial Health Care  
Worcester, MA

Mitchell H. Sokoloff is founding chair of the Department of Urology at UMass Memorial Health Care and UMass Medical School in Worcester, Massachusetts. Dr. Sokoloff is board certified in urology, with clinical specialties in the treatment of prostate, kidney and testis cancer. His expertise includes robotic prostatectomy, nerve-sparing prostatectomy, nephron-sparing partial nephrectomy and retroperitoneal lymph node dissection. He has particular expertise in the management of high risk, locally-advanced and recurrent prostate, kidney and testis cancer. He has received national peer-reviewed funding for basic and translational research. Dr. Sokoloff came to Worcester in March 2014 from his position as professor of surgery and chief of the urology division of the Department of Surgery at the University of Arizona College of Medicine in Tucson, Arizona, a position he had held since 2008. He earned his undergraduate and medical degrees from Stanford University in Palo Alto, California, and completed a residency in urology at UCLA School of Medicine in Los Angeles, as well as a fellowship in molecular urology and therapeutics at the University of Virginia in Charlottesville, Virginia.

At the University of Arizona, Dr. Sokoloff developed a nationally recognized program in genitourinary oncology that incorporated novel anti-cancer agents and technologies as a complement to conventional surgical therapy. Previously, Dr. Sokoloff was chief of urologic oncology in the Division of Urology and Renal Transplantation and director of robotic surgery in the Department of Surgery at Oregon Health and Science University in Portland, Oregon. Prior to that, he was director of Urologic Oncology in the Division of Urology at the University of Chicago. He is a member of the American Association of Cancer Research, American Urological Association, American College of Surgeons, Society for Urologic Oncology, Society of Urologic Chairs and Program Directors, and the Society for Basic Urologic Research. He is the author or co-author of more than forty peer-reviewed publications, numerous book chapters and abstracts and has presented at a wide range of regional, national and international meetings.

Mitchell H. Sokoloff, MD, FACS, has no relevant financial relationships to disclose.

# AGENDA

## Friday, November 14, 2014

10:00am-12:00pm	Registration and Visit Exhibits
12:00-12:15pm	Welcome and Introduction E. David Crawford, MD
<b>12:15-2:15pm</b>	<b>SESSION I: STATE OF THE ART PRESENTATIONS Matt T. Rosenberg, MD - Moderator</b>
12:15-12:40pm	What To Do in the Uncomplicated BPH Patient Matt T. Rosenberg, MD
12:40-1:05pm	Utility of NaF PET/CT and Other Imaging Modalities in Prostate Cancer Philip J. Koo, MD
1:05-1:30pm	Management of OAB in Men and Women Matt T. Rosenberg, MD
1:30-1:55pm	Increasing Role of Biomarkers for Prostate Cancer and Bladder Cancer Detection Erik P. Castle, MD
1:55-2:15pm	Updates in Radiation (Photon, Proton, Electron, Gamma, Alpha) David C. Beyer, MD, FACR, FACRO, FASTRO
2:15-2:30pm	Break and Visit Exhibits
2:30-3:30pm	Cases and Point Counterpoint Discussion Panel Robert E. Donohue, MD - Moderator
<b>3:30-6:30pm</b>	<b>SESSION II: LOCALIZED PROSTATE CANCER David C. Beyer, MD, FACR, FACRO, FASTRO - Moderator</b>
3:30-3:55pm	Point-Counterpoint - Active Surveillance: Should Men Be on a 5 alpha Reductase Inhibitor? Pro: E. David Crawford, MD Con: Mitchell H. Sokoloff, MD, FACS
3:55-4:20pm	Targeting Therapy in Prostate Cancer E. David Crawford, MD
4:20-4:45pm	Advancing Patient Access to Novel, Advanced Cancer Care Steven E. Finkelstein, MD
4:45-5:15pm	Point Counterpoint - NaF PET/CT Should Be the Imaging Agent of Choice to Evaluate for Bone Metastases in Prostate Cancer Pro: Philip J. Koo, MD Con: Gerald W. Chodak, MD
5:15-5:45pm	Point Counterpoint: New Paradigm for Metastatic Prostate Cancer Early Chemo: Daniel P. Petrylak, MD Delayed Chemo: Gerald W. Chodak, MD
5:45-6:30pm	Cases and Discussion Panel Robert E. Donohue, MD - Moderator
6:30-7:30pm	Welcome Reception and Visit Exhibits

## Saturday, November 15, 2014

8:00-9:00am	Industry-supported Breakfast Symposium Sponsored by Prostate Conditions Educational Council
<b>9:00am-12:00pm</b>	<b>SESSION III: ADVANCED PROSTATE CANCER E. David Crawford, MD - Moderator</b>
9:00-9:25am	Progress in and Challenges of Androgen Deprivation Therapy E. David Crawford, MD
9:25-9:50am	Novel Secondary Hormonal Therapies for Prostate Cancer Erik P. Castle, MD
9:50-10:15am	The Latest on Bone Health and Radiopharmaceuticals Steven E. Finkelstein, MD
10:15-10:30am	Break and Visit Exhibits
10:30-11:45am	Cases Discussions: Localized and Advance Prostate Cancer Panel

12:00-1:00pm	Industry-supported Lunch Symposium Supported by Astellas and Medivation
<b>1:00-3:30pm</b>	<b>SESSION IV: OTHER GENITOURINARY DISORDERS Karl J. Kreder, MD, MBA - Moderator</b>
1:00-1:25pm	Neuromodulation Update: Tips for Success Karl J. Kreder, MD, MBA
1:25-1:50pm	Systemic Therapies for Renal Cell Carcinoma Mitchell H. Sokoloff, MD, FACS
1:50-2:15pm	Molecular Genetics of Renal Cell Carcinoma: Does Molecular Profiling of Tumors Affect Patient Treatment? Thai H. Ho, MD
2:15-2:40pm	Treatment Options for the Small Renal Mass Erik P. Castle, MD
2:40-3:05pm	Point Counterpoint - Observe Lesions Less Than 1-2cm? Pro: Robert E. Donohue, MD Con: Erik P. Castle, MD
3:05-3:30pm	Cases and Point Counterpoint Discussion Panel Robert E. Donohue, MD - Moderator
3:30-3:45pm	Break and Visit Exhibits
<b>3:45-6:15pm</b>	<b>SESSION V: BLADDER AND UROTHELIAL CANCER Donald L. Lamm, MD, FACS - Moderator</b>
3:45-4:10pm	BCG Immunotherapy: What's New? Erik P. Castle, MD
4:10-4:35pm	Role of Neoadjuvant Chemotherapy for Upper Tract UCC Erik P. Castle, MD
4:35-5:00pm	New Challenges in Treating Bladder Cancer Mitchell H. Sokoloff, MD, FACS
5:00-5:25pm	Photocure and NBI: Is This the New Standard of Care? Donald L. Lamm, MD
5:25-6:15pm	Cases and Point Counterpoint Discussion Panel Erik P. Castle, MD - Moderator
Evening	On Own

## Sunday, November 16, 2014

7:00-8:00am	CME Accredited Breakfast Symposium Supported by Bayer HealthCare
<b>8:00-11:15am</b>	<b>SESSION VI: CASES AND PRACTICAL ADVICE FOR UROLOGISTS Karl J. Kreder, MD, MBA - Moderator</b>
8:00-8:20am	How the PSA Guidelines Missed the Mark with Primary Care, and How to Fix Them Matt T. Rosenberg, MD
8:20-8:40am	Testosterone and Acute Renal Failure: An Update on GnRH Antagonists and LHRH Agonists E. David Crawford, MD
8:40-9:00am	What the Urologist Needs to Know About Sequencing New Agents in CRPC Daniel P. Petrylak, MD
9:00-9:20am	Point-Counterpoint: Radiopharmaceuticals Should Be Administered by a Radiation Oncologist Pro: Steven E. Finkelstein, MD Con: Phillip J. Koo, MD
9:20-9:35am	Break and Visit Exhibits
9:35-9:55am	Hereditary Kidney Cancer Syndromes Thai H. Ho, MD
9:55-10:15am	Current Issues in Female Urology, Including SUI Karl J. Kreder, MD, MBA
10:15-10:35am	Managing the Patient with Interstitial Cystitis Karl J. Kreder, MD, MBA
10:35-11:15am	Point Counterpoint Discussion Panel Robert E. Donohue, MD - Moderator
11:15am	Adjourn



# ACKNOWLEDGMENT of CORPORATE SUPPORT

The Organizers Would Like to Thank the Following Organizations for their support:  
(Supporters and Exhibitors as of November 1, 2014)

## GOLD SUPPORTERS

Astellas Pharma US/Medivation, Inc.

## SILVER SUPPORTERS

AbbVie

Bayer HealthCare Pharmaceuticals

Dendreon Corporation

Janssen Biotech

## BRONZE SUPPORTERS

Allergan

Genomic Health

Prostate Conditions Education Council

## EXHIBITORS

Astellas Pharma US/Medivation, Inc.

Bayer HealthCare Pharmaceuticals

Dendreon Corporation

Ferring Pharmaceuticals

Genomic Health

HealthTronics, Inc.

Janssen Biotech

Laserent, Inc.

Olympus America, Inc.

Sanofi Oncology

Strand Diagnostics - Know Error

Sponsored by Grand Rounds in Urology

**GRAND ROUNDS**  
in UROLOGY™

Meeting management services provided by  
**CJP Medical Communications**  
A Division of Carden Jennings Publishing Co., Ltd.

375 Greenbrier Drive, Suite 100  
Charlottesville, VA 22901  
434-817-200 • [www.cjp.com](http://www.cjp.com)

